clinical trial · NCT05354141
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
Direct Biologics, LLC·phase3·recruiting·n = 970
Acute Respiratory Distress SyndromeARDSExoFloIntravenous normal saline
brief summary
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
started
Jul 1, 2022
primary completion
Nov 30, 2027
completion
Dec 31, 2027
last updated
Feb 23, 2026
detailed description
This is a Phase III, multicenter, randomized, double-blinded, placebo-controlled trial for the treatment of moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
official title
Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Moderate-to-Severe ARDS: A Phase III Clinical Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol